Table 4. Association of H1-receptor antagonists (H1RAs) use with prevalent NAFLD according to selected risk factors; NHANES, 2001 – 2006.
| Crude OR (95% CI) | Adjusted¥ OR (95% CI) |
|
|---|---|---|
| Sex | ||
| Male | 1.12 (0.76 – 1.65) | 1.20 (0.62 – 2.32) |
| Female | 0.65 (0.40 – 1.06) | 0.34 (0.11 – 1.13) |
| Age | ||
| ≤ 60 yrs. | 0.74 (0.53 – 1.02) | 0.74 (0.39 – 1.40) |
| > 60 yrs. | 1.16 (0.63 – 2.13) | 1.05 (0.39 – 2.82) |
| BMI | ||
| < 25 | 0.48 (0.19 – 1.19) | 0.79 (0.17 – 3.62) |
| 25-30 | 0.94 (0.60 – 1.48) | 1.01 (0.46 – 2.23) |
| ≥ 30 | 0.78 (0.50 – 1.21) | 0.54 (0.24 – 1.24) |
| IR | ||
| No | 0.57 (0.28 – 1.13) | 0.83 (0.38 – 1.78) |
| Yes | 0.96 (0.55 – 1.69) | 0.77 (0.37 – 1.62) |
OR, odds ratio; CI, confidence interval; IR, insulin resistance
¥
Unconditional logistic regression model, adjusted for PPIs and H2RAs use, age, sex, ethnicity, socioeconomic status, waist circumference, physical activity, smoking status, insulin resistance (IR), systolic/diastolic blood pressure, and hypercholesterolemia